Healthcare & Pharma Exports from India​

India’s healthcare and pharmaceutical sector supplies generic medicines, vaccines and healthcare products to markets globally, with more firms moving into higher‑value products, advanced manufacturing and research-led services.

As pharma export businesses scale, many companies are also looking at overseas expansion to acquire new customers or invest in new manufacturing capacity. At the same time, they must manage long working-capital cycles, foreign-currency exposures, and evolving pharma regulations where the role of technology in healthcare including AI can help improve control and efficiency.

• Growing demand for pharmaceuticals, vaccines, diagnostics and specialized healthcare products
• Scope for Indian businesses to move further into higher-value areas such as CDMO and CRAMS services, biologics, MedTech, diagnostics and digital health - where technology and the future of healthcare such AI can improve quality, speed and traceability.
• Trade corridors such as the US, Europe, the UK, and the Middle East continue to offer business opportunities for market expansion in pharma trading, partnerships and investment.

• Healthcare regulations and compliance requirements in key export markets can be complex and time-sensitive for a scaling export business.
• R&D, plant expansion and technology upgrades can create significant funding needs.
• Long receivable cycles, supplier dependencies and currency volatility can put pressure on liquidity and margins. particularly for business models on pharma trading and cross-border growth.

HSBC supports healthcare and pharma businesses with corporate banking solutions designed for international growth, innovation and operational resilience.

We can help businesses manage trade flows, working capital, liquidity, foreign-currency exposure and cross-border banking needs as they expand exports, invest in regulated manufacturing capacity, strengthen treasury models or enter new markets.